Ayşe Merve Şenol

Ayşe Merve Şenol

Auto-generated profile, based on publicly available information

Ayşe Merve Şenol

Department of Medical Services and Techniques, Hamidiye Vocational School of Health Services, University of Health Sciences, Üsküdar, 34668, İstanbul, Türkiye

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 February 2026 in RSC Advances
Verified
Journal Article
Open access
WZWajeeha Zareen
Wajeeha Zareen
NANadeem Ahmed
Nadeem Ahmed
FTFeyzi Sinan Tokali
Feyzi Sinan Tokali
TITalha Islam
Talha Islam
MAMariya Al-Rashida
Mariya Al-Rashida
MIMohammad Shahidul Islam
Mohammad Shahidul Islam
6-Hydroxychromone-derived hydrazones were synthesized and evaluated for their in vitro hCA I–II and AChE inhibitory activities, along with antioxidant properties.

19 January 2023 in Research on Chemical Intermediates
Verified
Journal Article
Closed access
PDF file
AŞAyşe Merve Şenol
Ayşe Merve Şenol
EBEbru Bozkurt
Ebru Bozkurt

4 February 2026 in Future Medicinal Chemistry
Verified
Journal Article
Closed access
PTPelin Tokalı
Pelin Tokalı
AŞAyşe Merve Şenol
Ayşe Merve Şenol
ŞAŞeyma Ateşoğlu
Şeyma Ateşoğlu
FÇFurkan Çakır
Furkan Çakır
HŞHalil ŞENOL
Halil ŞENOL
FAFahri Akbaş
Fahri Akbaş
Lung cancer remains a leading cause of cancer-related deaths, largely due to therapy resistance and toxicity. This study develops novel quinazolinone-thiazolidinedione (TZD) hybrids by combining two anticancer pharmacophores to achieve more selective and potent EGFR inhibitors. A total of 14 quinazolinone-TZD hybrids were synthesized and characterized. Their cytotoxicity was evaluated in A549 lung adenocarcinoma and BEAS-2B normal bronchial cells. EGFR binding was analyzed via molecular docking and MM-GBSA, with 500 ns molecular dynamics simulations supporting the stability of selected complexes. ADME predictions assessed drug-likeness and oral bioavailability. Several compounds showed selective cytotoxicity against A549 cells, with compound 9 (thiophen-2-ylmethyl substituent) emerging as the most active (IC50 = 3.85 μM, SI = 36.0), outperforming gefitinib (IC50 = 9.59 μM, SI = 1.9) and exhibiting higher selectivity than sorafenib (IC50 = 3.24 μM, SI = 5.4). Computational analyses revealed key interactions with EGFR residues (Cys-797, Arg-841, Asn-842, and Phe-997), supported by stable molecular dynamics behavior and favorable ADME predictions. These findings indicate that the synthesized hybrids, particularly compound 9, represent promising leads for selective EGFR-targeted lung cancer therapy and support further optimization.

1 October 2021 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
KKKubilay Korkmaz
Kubilay Korkmaz
BBBurcu Meryem Beşer
Burcu Meryem Beşer
AŞAyşe Merve Şenol
Ayşe Merve Şenol
YOYavuz Onganer
Yavuz Onganer

14 February 2026 in Journal of Molecular Structure
Verified
Journal Article
Closed access
FTFeyzi Sinan Tokalı
Feyzi Sinan Tokalı
GTGurbet Çelik Turgut
Gurbet Çelik Turgut
AŞAyşe Merve Şenol
Ayşe Merve Şenol
PTPelin Tokalı
Pelin Tokalı
FÇFurkan Çakır
Furkan Çakır
ASAlaattin SEN
Alaattin SEN

18 August 2023 in Industrial & Engineering Chemistry Research
Verified
Journal Article
Open access
MÇMehmet Çopur
Mehmet Çopur
AŞAyşe Merve Şenol
Ayşe Merve Şenol
TPTurgay Pekdemir
Turgay Pekdemir
YOYavuz Onganer
Yavuz Onganer